1i5v

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
(New page: 200px<br /><applet load="1i5v" size="450" color="white" frame="true" align="right" spinBox="true" caption="1i5v" /> '''SOLUTION STRUCTURE OF 2-(PYRIDO[1,2-E]PURIN-...)
Current revision (18:40, 29 November 2023) (edit) (undo)
 
(13 intermediate revisions not shown.)
Line 1: Line 1:
-
[[Image:1i5v.gif|left|200px]]<br /><applet load="1i5v" size="450" color="white" frame="true" align="right" spinBox="true"
 
-
caption="1i5v" />
 
-
'''SOLUTION STRUCTURE OF 2-(PYRIDO[1,2-E]PURIN-4-YL)AMINO-ETHANOL INTERCALATED IN THE DNA DUPLEX D(CGATCG)2'''<br />
 
-
==Overview==
+
==SOLUTION STRUCTURE OF 2-(PYRIDO[1,2-E]PURIN-4-YL)AMINO-ETHANOL INTERCALATED IN THE DNA DUPLEX D(CGATCG)2==
-
The solution structure of the complex formed between d(CGATCG)(2) and, 2-(pyrido[1,2-e]purin-4-yl)amino-ethanol, a new antitumor drug under, design, has been resolved using NMR spectroscopy and restrained molecular, dynamic simulations. The drug molecule intercalates between each of the, CpG dinucleotide steps with its side chain lying in the minor groove., Analysis of NMR data establishes a weak stacking interaction between the, intercalated ligand and the DNA bases; however, the drug/DNA affinity is, enhanced by a hydrogen bond between the hydroxyl group of the end of the, intercalant side chain and the amide group of guanine G6. Unrestrained, molecular dynamic simulations performed in a water box confirm the, stability of the intercalation model. The structure of the intercalated, complex enables insight into the structure-activity relationship, allowing, rationalization of the design of new antineoplasic agents.
+
<StructureSection load='1i5v' size='340' side='right'caption='[[1i5v]]' scene=''>
 +
== Structural highlights ==
 +
<table><tr><td colspan='2'>[[1i5v]] is a 2 chain structure. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1I5V OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=1I5V FirstGlance]. <br>
 +
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">Solution NMR</td></tr>
 +
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=PPZ:2-(PYRIDO[1,2-E]PURIN-4-YL)AMINO-ETHANOL'>PPZ</scene></td></tr>
 +
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=1i5v FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1i5v OCA], [https://pdbe.org/1i5v PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=1i5v RCSB], [https://www.ebi.ac.uk/pdbsum/1i5v PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=1i5v ProSAT]</span></td></tr>
 +
</table>
 +
<div style="background-color:#fffaf0;">
 +
== Publication Abstract from PubMed ==
 +
The solution structure of the complex formed between d(CGATCG)(2) and 2-(pyrido[1,2-e]purin-4-yl)amino-ethanol, a new antitumor drug under design, has been resolved using NMR spectroscopy and restrained molecular dynamic simulations. The drug molecule intercalates between each of the CpG dinucleotide steps with its side chain lying in the minor groove. Analysis of NMR data establishes a weak stacking interaction between the intercalated ligand and the DNA bases; however, the drug/DNA affinity is enhanced by a hydrogen bond between the hydroxyl group of the end of the intercalant side chain and the amide group of guanine G6. Unrestrained molecular dynamic simulations performed in a water box confirm the stability of the intercalation model. The structure of the intercalated complex enables insight into the structure-activity relationship, allowing rationalization of the design of new antineoplasic agents.
-
==About this Structure==
+
Solution structure of 2-(pyrido[1,2-e]purin-4-yl)amino-ethanol intercalated in the DNA duplex d(CGATCG)2.,Favier A, Blackledge M, Simorre JP, Crouzy S, Dabouis V, Gueiffier A, Marion D, Debouzy JC Biochemistry. 2001 Jul 31;40(30):8717-26. PMID:11467931<ref>PMID:11467931</ref>
-
1I5V is a [http://en.wikipedia.org/wiki/Protein_complex Protein complex] structure of sequences from [http://en.wikipedia.org/wiki/ ] with PPZ as [http://en.wikipedia.org/wiki/ligand ligand]. Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=1I5V OCA].
+
-
==Reference==
+
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
-
Solution structure of 2-(pyrido[1,2-e]purin-4-yl)amino-ethanol intercalated in the DNA duplex d(CGATCG)2., Favier A, Blackledge M, Simorre JP, Crouzy S, Dabouis V, Gueiffier A, Marion D, Debouzy JC, Biochemistry. 2001 Jul 31;40(30):8717-26. PMID:[http://ispc.weizmann.ac.il//pmbin/getpm?pmid=11467931 11467931]
+
</div>
-
[[Category: Protein complex]]
+
<div class="pdbe-citations 1i5v" style="background-color:#fffaf0;"></div>
-
[[Category: Blackledge, M.]]
+
== References ==
-
[[Category: Debousy, J.C.]]
+
<references/>
-
[[Category: Favier, A.]]
+
__TOC__
-
[[Category: Marion, D.]]
+
</StructureSection>
-
[[Category: Simorre, J.P.]]
+
[[Category: Large Structures]]
-
[[Category: PPZ]]
+
[[Category: Blackledge M]]
-
[[Category: double helix]]
+
[[Category: Debousy JC]]
-
[[Category: drug-dna complex]]
+
[[Category: Favier A]]
-
 
+
[[Category: Marion D]]
-
''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Sun Nov 25 03:39:39 2007''
+
[[Category: Simorre JP]]

Current revision

SOLUTION STRUCTURE OF 2-(PYRIDO[1,2-E]PURIN-4-YL)AMINO-ETHANOL INTERCALATED IN THE DNA DUPLEX D(CGATCG)2

PDB ID 1i5v

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/1i5v"
Personal tools